A new approach to a Covid-19 nasal vaccine shows early promise
A New Approach to a Covid-19 Nasal Vaccine Shows Early Promise
Researchers in Germany have developed a nasal vaccine that may halt SARS-CoV-2 replication in the nasal and throat regions, where the virus initially infects the body. Testing on hamsters revealed that two doses of the vaccine—crafted from a live, attenuated coronavirus—prevented the pathogen from replicating in the upper airways, effectively blocking illness. This achievement, known as “sterilizing immunity,” marks a significant milestone in pandemic vaccine development.
Related Article: WHO Experts Revise Covid-19 Vaccine Advice
While the German vaccine has promising results, several challenges remain before it reaches public health systems. Other nasal vaccines are already in use or nearing completion in trials, including those launched by China and India last fall. However, their efficacy data has not yet been fully disclosed, leaving uncertainty about their real-world effectiveness in humans.
Related Article: China Approves Its First mRNA Covid-19 Vaccine
The U.S. continues to grapple with ongoing cases of the virus, despite the pandemic’s most severe phases passing. Daily deaths persist, as infections linger in everyday life. Experts warn that the virus could evolve into a more contagious or harmful strain, especially if it spreads among people and animals. For vulnerable populations, including the elderly and immunocompromised, even mild infections remain a concern.
“Imagine positioning firefighters beneath a smoke alarm in your home,” said Emanuel Wyler, a scientist at the Max Delbruck Center for Molecular Medicine. “They can swiftly extinguish the fire, but if they’re stationed two miles away, they have to travel before the blaze spreads extensively.”
Scientists are focusing on enhancing mucosal immunity, which targets the tissues lining the upper respiratory tract. This strategy may offer faster protection than systemic immunity from injections, which primarily acts in the bloodstream. IgA antibodies, produced by mucosal vaccines, are more effective at neutralizing the virus due to their four-arm structure, which allows them to bind to multiple sites on pathogens. In contrast, IgG antibodies have only two arms, making them less versatile against evolving variants.
The German vaccine builds on a historic method of weakening viruses to create immunity. Early vaccines against anthrax and rabies in the 1870s used heat and chemicals to reduce pathogen potency. The current approach, called codon pair deoptimization, modifies the virus’s genetic code to disrupt cellular translation, rendering it harmless while still triggering an immune response. “It’s like altering the font of a text—making it harder to read,” Wyler explained.
Recent trials in hamsters, published in Nature Microbiology, demonstrated that the nasal vaccine outperformed both mRNA and adenovirus-based alternatives. Two doses generated a stronger immune response than one dose of the latter, suggesting the live virus mimics natural infection more closely. This could lead to more robust and rapid protection, potentially reducing the spread of the virus in communities.
